These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38621924)

  • 1. Clinical, experimental and pathophysiological effects of Yaq-001: a non-absorbable, gut-restricted adsorbent in models and patients with cirrhosis.
    Liu J; MacNaughtan J; Kerbert AJC; Portlock T; Martínez Gonzalez J; Jin Y; Clasen F; Habtesion A; Ji H; Jin Q; Phillips A; De Chiara F; Ingavle G; Jimenez C; Zaccherini G; Husi K; Rodriguez Gandia MA; Cordero P; Soeda J; McConaghy L; Oben J; Church K; Li JV; Wu H; Jalan A; Gines P; Solà E; Eaton S; Morgan C; Kowalski M; Green D; Gander A; Edwards LA; Cox IJ; Cortez-Pinto H; Avery T; Wiest R; Durand F; Caraceni P; Elosua R; Vila J; Pavesi M; Arroyo V; Davies N; Mookerjee RP; Vargas V; Sandeman S; Mehta G; Shoaie S; Marchesi J; Albillos A; Andreola F; Jalan R
    Gut; 2024 Jun; 73(7):1183-1198. PubMed ID: 38621924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The microbiota in cirrhosis and its role in hepatic decompensation.
    Trebicka J; Macnaughtan J; Schnabl B; Shawcross DL; Bajaj JS
    J Hepatol; 2021 Jul; 75 Suppl 1(Suppl 1):S67-S81. PubMed ID: 34039493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis.
    Sorribas M; Jakob MO; Yilmaz B; Li H; Stutz D; Noser Y; de Gottardi A; Moghadamrad S; Hassan M; Albillos A; Francés R; Juanola O; Spadoni I; Rescigno M; Wiest R
    J Hepatol; 2019 Dec; 71(6):1126-1140. PubMed ID: 31295531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in the prevention and treatment of decompensated cirrhosis and acute-on-chronic liver failure (ACLF) and the role of biomarkers.
    Trebicka J; Hernaez R; Shawcross DL; Gerbes AL
    Gut; 2024 May; 73(6):1015-1024. PubMed ID: 38527788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simvastatin Prevents Progression of Acute on Chronic Liver Failure in Rats With Cirrhosis and Portal Hypertension.
    Tripathi DM; Vilaseca M; Lafoz E; Garcia-Calderó H; Viegas Haute G; Fernández-Iglesias A; Rodrigues de Oliveira J; García-Pagán JC; Bosch J; Gracia-Sancho J
    Gastroenterology; 2018 Nov; 155(5):1564-1577. PubMed ID: 30055171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations in Gut Microbiome in Cirrhosis as Assessed by Quantitative Metagenomics: Relationship With Acute-on-Chronic Liver Failure and Prognosis.
    Solé C; Guilly S; Da Silva K; Llopis M; Le-Chatelier E; Huelin P; Carol M; Moreira R; Fabrellas N; De Prada G; Napoleone L; Graupera I; Pose E; Juanola A; Borruel N; Berland M; Toapanta D; Casellas F; Guarner F; Doré J; Solà E; Ehrlich SD; Ginès P
    Gastroenterology; 2021 Jan; 160(1):206-218.e13. PubMed ID: 32941879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure.
    Trebicka J; Bork P; Krag A; Arumugam M
    Nat Rev Gastroenterol Hepatol; 2021 Mar; 18(3):167-180. PubMed ID: 33257833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of artesunate supplementation on bacterial translocation and dysbiosis of gut microbiota in rats with liver cirrhosis.
    Chen YX; Lai LN; Zhang HY; Bi YH; Meng L; Li XJ; Tian XX; Wang LM; Fan YM; Zhao ZF; Han DW; Ji C
    World J Gastroenterol; 2016 Mar; 22(10):2949-59. PubMed ID: 26973391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment of a murine model of acute-on-chronic liver failure with multi-organ dysfunction.
    Nautiyal N; Maheshwari D; Tripathi DM; Kumar D; Kumari R; Gupta S; Sharma S; Mohanty S; Parasar A; Bihari C; Biswas S; Rastogi A; Maiwall R; Kumar A; Sarin SK
    Hepatol Int; 2021 Dec; 15(6):1389-1401. PubMed ID: 34435344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Intestinal Microbiota Collected at Hospital Admission and Outcomes of Patients With Cirrhosis.
    Bajaj JS; Vargas HE; Reddy KR; Lai JC; O'Leary JG; Tandon P; Wong F; Mitrani R; White MB; Kelly M; Fagan A; Patil R; Sait S; Sikaroodi M; Thacker LR; Gillevet PM
    Clin Gastroenterol Hepatol; 2019 Mar; 17(4):756-765.e3. PubMed ID: 30036646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toll-like receptor 4 is a therapeutic target for prevention and treatment of liver failure.
    Engelmann C; Sheikh M; Sharma S; Kondo T; Loeffler-Wirth H; Zheng YB; Novelli S; Hall A; Kerbert AJC; Macnaughtan J; Mookerjee R; Habtesion A; Davies N; Ali T; Gupta S; Andreola F; Jalan R
    J Hepatol; 2020 Jul; 73(1):102-112. PubMed ID: 31987990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
    Arab JP; Martin-Mateos RM; Shah VH
    Hepatol Int; 2018 Feb; 12(Suppl 1):24-33. PubMed ID: 28550391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut-liver axis signaling in portal hypertension.
    Simbrunner B; Mandorfer M; Trauner M; Reiberger T
    World J Gastroenterol; 2019 Oct; 25(39):5897-5917. PubMed ID: 31660028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Gut Microbiota in Liver Disease.
    Brenner DA; Paik YH; Schnabl B
    J Clin Gastroenterol; 2015; 49 Suppl 1(0 1):S25-7. PubMed ID: 26447960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology.
    Trebicka J; Fernandez J; Papp M; Caraceni P; Laleman W; Gambino C; Giovo I; Uschner FE; Jimenez C; Mookerjee R; Gustot T; Albillos A; Bañares R; Janicko M; Steib C; Reiberger T; Acevedo J; Gatti P; Bernal W; Zeuzem S; Zipprich A; Piano S; Berg T; Bruns T; Bendtsen F; Coenraad M; Merli M; Stauber R; Zoller H; Ramos JP; Solè C; Soriano G; de Gottardi A; Gronbaek H; Saliba F; Trautwein C; Özdogan OC; Francque S; Ryder S; Nahon P; Romero-Gomez M; Van Vlierberghe H; Francoz C; Manns M; Garcia E; Tufoni M; Amoros A; Pavesi M; Sanchez C; Curto A; Pitarch C; Putignano A; Moreno E; Shawcross D; Aguilar F; Clària J; Ponzo P; Jansen C; Vitalis Z; Zaccherini G; Balogh B; Vargas V; Montagnese S; Alessandria C; Bernardi M; Ginès P; Jalan R; Moreau R; Angeli P; Arroyo V;
    J Hepatol; 2020 Oct; 73(4):842-854. PubMed ID: 32673741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mosapride Stabilizes Intestinal Microbiota to Reduce Bacterial Translocation and Endotoxemia in CCl
    Xu H; Xiong J; Xu J; Li S; Zhou Y; Chen D; Cai X; Ping J; Deng M; Chen J
    Dig Dis Sci; 2017 Oct; 62(10):2801-2811. PubMed ID: 28815345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, controlled clinical trial of the DIALIVE liver dialysis device versus standard of care in patients with acute-on- chronic liver failure.
    Agarwal B; Cañizares RB; Saliba F; Ballester MP; Tomescu DR; Martin D; Stadlbauer V; Wright G; Sheikh M; Morgan C; Alzola C; Lavin P; Green D; Kumar R; Sacleux SC; Schilcher G; Koball S; Tudor A; Minten J; Domenech G; Aragones JJ; Oettl K; Paar M; Waterstradt K; Bode-Boger SM; Ibáñez-Samaniego L; Gander A; Ramos C; Chivu A; Stange J; Lamprecht G; Sanchez M; Mookerjee RP; Davenport A; Davies N; Pavesi M; Andreola F; Albillos A; Cordingley J; Schmidt H; Carbonell-Asins JA; Arroyo V; Fernandez J; Mitzner S; Jalan R
    J Hepatol; 2023 Jul; 79(1):79-92. PubMed ID: 37268222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised clinical trial: the effects of a multispecies probiotic vs. placebo on innate immune function, bacterial translocation and gut permeability in patients with cirrhosis.
    Horvath A; Leber B; Schmerboeck B; Tawdrous M; Zettel G; Hartl A; Madl T; Stryeck S; Fuchs D; Lemesch S; Douschan P; Krones E; Spindelboeck W; Durchschein F; Rainer F; Zollner G; Stauber RE; Fickert P; Stiegler P; Stadlbauer V
    Aliment Pharmacol Ther; 2016 Nov; 44(9):926-935. PubMed ID: 27593544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Pose E; Napoleone L; Amin A; Campion D; Jimenez C; Piano S; Roux O; Uschner FE; de Wit K; Zaccherini G; Alessandria C; Angeli P; Bernardi M; Beuers U; Caraceni P; Durand F; Mookerjee RP; Trebicka J; Vargas V; Andrade RJ; Carol M; Pich J; Ferrero J; Domenech G; Llopis M; Torres F; Kamath PS; Abraldes JG; Solà E; Ginès P
    Lancet Gastroenterol Hepatol; 2020 Jan; 5(1):31-41. PubMed ID: 31607677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of RIPK1 mediated cell death in acute on chronic liver failure.
    Kondo T; Macdonald S; Engelmann C; Habtesion A; Macnaughtan J; Mehta G; Mookerjee RP; Davies N; Pavesi M; Moreau R; Angeli P; Arroyo V; Andreola F; Jalan R
    Cell Death Dis; 2021 Dec; 13(1):5. PubMed ID: 34921136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.